What does PERPHARM do?

PERPHARM is a pharmacy in Péruwelz. Public Limited, started on 17 October 2002, 1 establishment.

What is the address of PERPHARM?

The registered office of PERPHARM is located at Rue Pont-à-la-Faulx(PER) 26-28, 7600 Péruwelz.

Is PERPHARM still active?

No. The CBE lists PERPHARM with legal situation “Opening faillissement”. The date of the court ruling is published in the Belgian Official Gazette; the register does not carry it.

Is PERPHARM registered on Peppol?

Yes, PERPHARM is registered on the Peppol network with ID 0208:0478611658.

What is the enterprise number of PERPHARM?

The enterprise number of PERPHARM is BE0478611658.

When was PERPHARM founded?

PERPHARM was founded on 17 October 2002.

Who are the directors of PERPHARM?

According to the 2022 annual accounts, the directors of PERPHARM are: RISSPHAR SRL.

Is PERPHARM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Opening faillissement according to the CBE, started on 17 October 2002; 2 annual accounts filed, latest fiscal year 2022; 1 directors known from the annual account.

How much profit did PERPHARM make in 2022?

PERPHARM recorded a loss after taxes of € 145,279 in financial year 2022.

What is the revenue of PERPHARM?

As a small company, PERPHARM is not required to publish revenue in its annual accounts. In financial year 2022, its added value was € 320,637.

How much does an employee at PERPHARM earn?

The average wage cost per full-time employee at PERPHARM was € 46,600 in 2022: staff costs of € 358,736 for 7.7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PERPHARM have?

According to the 2022 annual accounts, PERPHARM has 7.7 full-time equivalents (FTE).

PERPHARM (Public Limited) - Péruwelz - BE0478611658

Dossier PERPHARM, printed on 30 October 2026 from databakkes.be/en/0478611658/perpharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 59 % of short-term debt in 2022; threshold 65 %.
Legal situation KBO

Opening faillissement according to the CBE.

Financials

Financial year 2022

PERPHARM from Péruwelz, company number BE0478611658, closed financial year 2022 with a result of € -145,279 after tax. For that financial year PERPHARM recorded a gross margin of € 320,637 and equity of € 15,509. Compared with financial year 2021, the result moved from € 24,766 to € -145,279. The company made a loss. The buffer shrank hard: equity is 90 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 23, 2024.

What it is worth Shrank hard

€ 15,509

▼ 90% vs 2021

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -145,279

▼ still € 24,766 profit in 2021

Profit after tax over the fiscal year.

Cash in the bank

€ 173,602

▲ € 140,733 vs 2021

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -46,491.

People and assets in 2022

Full-time equivalents

7.7

▲ 1.4 vs 2021

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 358,736

▲ 47% vs 2021

€ 46,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 18,719

▼ 4% vs 2021

Book value of vehicles, furniture and equipment.

Debts at end 2022

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1 million

▼ 9% vs 2021

€ 82,393 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 412,558

▲ 67% vs 2021

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 68,191

▲ 20% vs 2021

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	Change 2021 → 2022
Gross margin	€ 344,900 Gross margin 2021: € 344,900 First fiscal year in the series	€ 320,637 Gross margin 2022: € 320,637 ▼ 7% vs 2021 (€ 344,900) Unfavourable step	▼ 7%
Profit after taxes	€ 24,766 Profit after taxes 2021: € 24,766 First fiscal year in the series	€ -145,279 Profit after taxes 2022: € -145,279 ▼ € 170,045 vs 2021 (€ 24,766) Unfavourable step	▼ € 170,045
Equity	€ 160,788 Equity 2021: € 160,788 First fiscal year in the series	€ 15,509 Equity 2022: € 15,509 ▼ 90% vs 2021 (€ 160,788) Unfavourable step	▼ 90%
Total debts	€ 1,702,852 Total debts 2021: € 1,702,852 First fiscal year in the series	€ 2,009,954 Total debts 2022: € 2,009,954 ▲ 18% vs 2021 (€ 1,702,852) Unfavourable step	▲ 18%
Cash	€ 32,868 Cash 2021: € 32,868 First fiscal year in the series	€ 173,602 Cash 2022: € 173,602 ▲ € 140,733 vs 2021 (€ 32,868) Favourable step	▲ € 140,733
Land & buildings	€ 970,137 Land & buildings 2021: € 970,137 First fiscal year in the series	€ 923,410 Land & buildings 2022: € 923,410 ▼ 5% vs 2021 (€ 970,137) Unchanged	▼ 5%
Retained profit	€ 98,788 Retained profit 2021: € 98,788 First fiscal year in the series	€ -46,491 Retained profit 2022: € -46,491 ▼ € 145,279 vs 2021 (€ 98,788) Unfavourable step	▼ € 145,279
Bank debt	€ 1,109,001 Bank debt 2021: € 1,109,001 First fiscal year in the series	€ 1,005,292 Bank debt 2022: € 1,005,292 ▼ 9% vs 2021 (€ 1,109,001) Favourable step	▼ 9%
Balance sheet total	€ 1,863,641 Balance sheet total 2021: € 1,863,641 First fiscal year in the series	€ 2,025,463 Balance sheet total 2022: € 2,025,463 ▲ 9% vs 2021 (€ 1,863,641) Unchanged	▲ 9%
Employees (FTE)	6.3 Employees (FTE) 2021: 6.3 First fiscal year in the series	7.7 Employees (FTE) 2022: 7.7 ▲ 1.4 vs 2021 (6.3) Unchanged	▲ 1.4

Key figures of PERPHARM, fiscal years 2021 to 2022, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2023 has not been filed yet; it was expected before 31 July 2024.

What happened to PERPHARM?

What happened at PERPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

PERPHARM is active according to the CBE. Legal situation: Opening faillissement.

Jan 23, 2024 New annual accounts for financial year 2022: loss of € 145,279 (▼ € 170,045 vs 2021). filed late Source: NBB ↗
2023 RISSPHAR SRL stepped down as director. NBB
2018 RISSPHAR SRL became a director. NBB
Nov 13, 2002 New establishment in Péruwelz. KBO
Oct 17, 2002 Start of the company according to the CBE. KBO

In short

From € 24,766 profit in 2021 to € 145,279 loss in 2022.

Best year ever: 2021, with € 24,766 profit.

On average € 41,600 of value added per employee in 2022.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2022 annual accounts

RISSPHAR SRL

Director · represented by Thibault RISSELIN

since 2018 · until 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Pont-à-la-Faulx(PER) 26-28

7600 Péruwelz

2.115.106.279

Rue Pont-à-la-Faulx(PER) 24

7600 Péruwelz

Active since 13 November 2002

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0478.611.658

VAT number

BE 0478.611.658

Registered office

Rue Pont-à-la-Faulx(PER) 26-28, 7600 Péruwelz

Names & denominations

PERPHARM

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Opening faillissement

Start date

17 October 2002

Peppol

Active · Active since 12 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗